Breast Cancer Diagnostics Market by Technique, Cancer Type, Component, Diagnostic Type, End-User

Description

List of Tables

[184 Pages Report] The Breast Cancer Diagnostics Market size was estimated at USD 6.54 billion in 2023 and expected to reach USD 7.04 billion in 2024, at a CAGR 7.79% to reach USD 11.06 billion by 2030.

Breast cancer diagnostics refer to tests and procedures conducted to determine the stage of breast cancer, including blood tests, magnetic resonance imaging, Positron emission tomography (PET) scan, and computerized tomography (CT scan). Breast cancer diagnostics tests determine whether the cancer or tumor is restricted to the breast or has spread to other body organs such as lymph nodes. The changing lifestyles and dietary and nutrition regime has led to hormonal changes and caused an increase in the number of women diagnosed with breast cancer and necessitated the development of breast cancer diagnostic tests. Furthermore, government initiatives and incentives to raise awareness about breast cancer and female reproductive health have caused a surge in the number of cancer screening programs worldwide. However, the high costs associated with breast cancer screening tests, genetic testing, and cancer drugs prevent patients from availing the services for treatment and diagnosis of cancer. The lack of skilled personnel to initiate appropriate treatment diagnosis procedures poses significant challenges for cancer care. However, integrating machine learning (ML) and artificial intelligence (AI) in breast cancer diagnostic procedures has enabled early breast cancer diagnosis. AI algorithms can identify missed cancers and breast tissue features and help predict future cancers.

KEY MARKET STATISTICS
Base Year [2023]	USD 6.54 billion
Estimated Year [2024]	USD 7.04 billion
Forecast Year [2030]	USD 11.06 billion
CAGR (%)	7.79%

Technique: Advancements in molecular and genomic biology advancing the penetration of molecular testing

Imaging tests for breast cancer include mammography, ultrasound, and magnetic resonance imaging. Mammography refers to a procedure that utilizes X-ray images of the breast to detect symptoms and signs of the presence of breast tumors. Digital mammography is preferred over analog mammography as it can detect tumor presence with less radiation dosage and is used by physicians to enable early cancer detection. Ultrasound tests utilize sound waves to detect cancer and indicate whether a solid mass of tissues inside the breast is malignant or benign. Rapid advancements in molecular biology have facilitated molecular tests aimed at detecting cancer at the genomic level. Molecular testing procedures detect the presence of cancer biomarkers and genomic variations or mutations within a cancer patient's genome to accurately determine the probability of cancer occurrence. These tests also enable patients with a family history of cancer to understand their chances of suffering from cancer.

Cancer Type: BRCA breast cancer is highly implicated as a hereditary breast cancer

The BRCA1 and BRCA2 genetic mutations are often implicated in breast cancer, and patients with the BRCA gene mutation are at a risk of suffering from breast cancer. The BRCA gene test and other BRCA testing methods determine if a patient's genome contains mutations that increase the risk of breast cancer. HER2 refers to a human protein called human epidermal growth factor receptor 2 (HER2) and is associated with a higher level of expression in breast cancer patients. HER2-positive breast cancer is cancer that gives a positive test result for the HER-2 protein. Immunohistochemistry tests determine the abundance of HER-2 proteins in phone breast cancer cells. HER2-positive cancers are associated with aggressive symptoms; however, they also respond better to breast cancer treatment regimes that target HER2 proteins specifically. Hormone receptor-positive or hormone-positive breast cancer cells have either estrogen (ER) or progesterone (PR) receptors or both. ER-positive or PR-positive tumors respond favorably to hormone therapy compared to ER-negative or PR-negative tumors. Physicians and medical professionals use these tests for effective medical decision-making.

Diagnostic Type: Advancing applications of non-ionizing imaging technologies for breast cancer diagnostics

The use of ionizing breast imaging technologies for breast cancer diagnostics involves procedures that utilize radiation to produce breast images. The most prevalent forms of ionizing imaging include mammography and tomosynthesis. Traditional mammography is a 2D imaging technique, whereas tomosynthesis offers a more detailed, layer-by-layer view of the breast, improving the detection rate of early-stage cancers and reducing the need for follow-up imaging. In contrast to ionizing imaging technologies, non-ionizing breast imaging techniques provide diagnostic capabilities without the use of radiation, offering a safer option for patients. The key technologies in this category include ultrasound and Magnetic Resonance Imaging (MRI). Breast ultrasound uses high-frequency sound waves to create images of the breast tissue and is often used as a complementary tool to mammography, especially in women with dense breast tissue. MRI, leveraging the power of strong magnetic fields and radio waves, is renowned for its high contrast resolution and is particularly useful for high-risk patients, as well as in the preoperative evaluation of breast cancer, assessing for multifocal or multicentric disease, and monitoring response to neoadjuvant chemotherapy.

End-User: High adoption of breast cancer diagnostics in the diagnostic laboratories

Diagnostic laboratories play a critical role in detecting and characterizing breast cancer, as they offer specialized testing services to detect biomarkers, gene mutations, and other relevant diagnostic indicators. These laboratories often prioritize high-throughput equipment and robust testing protocols that can handle many samples with precision and efficiency. Its need-based preference includes accessibility, rapid turnaround times, comprehensive test menus, and advanced diagnostic technologies. Hospitals and ambulatory surgery centers are primary points of care for patients who may require diagnostic services as part of their treatment plan. The preference is for integrated diagnostic solutions directly supporting treatment decision-making, typically involving imaging equipment like mammograms, ultrasound, and MRI machines, alongside biopsy procedures. Research and academic institutes focus on breast cancer research, including genetic studies, drug development, and early detection strategies. The availability of cutting-edge technology is crucial for these institutes, as their work often lays the groundwork for developing new diagnostic methods.

Regional Insights

The American breast cancer diagnostics market is highly developed due to the notable prevalence of breast cancer and the presence of multiple advanced imaging techniques in the region. According to the American Cancer Society, approximately 287,850 new cases of invasive breast cancer were anticipated to be diagnosed in the United States in 2022, bolstering the need for breast cancer diagnosis. Additionally, the growing geriatric population, ongoing cancer-related research activities, and the rising burden of different types of breast cancer have enhanced the need for breast cancer diagnosis in Germany, New Zealand, the United Kingdom, and several other European nations. Moreover, the significant involvement of the European government in breast cancer detection and diagnosis programs has elevated the market scope. In the Asia-Pacific region, China and India are the most prevalent regions for the increasing cases of breast cancer patients, raising the need for breast cancer diagnostics. Furthermore, the emerging campaigns and breast cancer awareness programs have highlighted the need for breast cancer diagnostics in Asian countries.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Breast Cancer Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Breast Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Breast Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 4D Path Inc., Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocept, Inc., Biodesix, Cardinal Health, Danaher Corporation, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fluxion Biosciences Inc. by Cell Microsystems, FUJIFILM Holdings Corporation, General Electric Company, Hologic, Inc., Illumina, Inc., Koninklijke Philips N.V., NanoString Technologies, Inc., NeoGenomics Laboratories, Olea Medical, OncoGenomX, Paragon Biosciences LLC by Catalent, Inc., Provista Diagnostics, Inc. by Todos Medical, Quest Diagnostics Incorporated, Siemens Healthcare Private Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Breast Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Technique
- Imaging
  - Analog Mammography
  - Breast Ultrasound System
  - Digital Mammography
  - Mammography
  - MRI Scan
  - PET/CT Scan

Molecular Testing
Tissue Biopsy Tests

Cancer Type
- BRCA Breast Cancer
- EGFR Mutation Test Breast Cancer
- ER & PR Breast Cancer
- HER 2 Breast Cancer

Component
- Consumables
  - Antibodies
  - Kits & Reagents
  - Probes

Instruments
- Biopsy Instruments
- Imaging Instruments
- Pathology-Based Instruments

Diagnostic Type
- Ionizing Breast Imaging Technologies
- Non-Ionizing Imaging Technologies

End-User
- Diagnostic Laboratories
- Hospitals & Ambulatory Surgery Center
- Research & Academic Institutes

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Breast Cancer Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Breast Cancer Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Breast Cancer Diagnostics Market?

4. What is the market share of the leading vendors in the Breast Cancer Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Breast Cancer Diagnostics Market?

Product Code: MRR-A26E0E57405A

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing incidence of breast cancer globally
  - 5.1.1.2. Favorable reimbursement framework for breast cancer diagnosis
  - 5.1.1.3. Growing number of breast cancer screening programs worldwide
- 5.1.2. Restraints
  - 5.1.2.1. High cost associated with breast cancer diagnostic tests
- 5.1.3. Opportunities
  - 5.1.3.1. Integration of artificial intelligence (AI) and machine learning (ML) in breast cancer diagnostic
  - 5.1.3.2. Ongoing research and development activities in cancer diagnostic techniques
- 5.1.4. Challenges
  - 5.1.4.1. Dearth of the skilled and trained professionals
5.2. Market Segmentation Analysis
- 5.2.1. Technique: Advancements in molecular and genomic biology advancing the penetration of molecular testing
- 5.2.2. Cancer Type: BRCA breast cancer is highly implicated as a hereditary breast cancer
- 5.2.3. Diagnostic Type: Advancing applications of non-ionizing imaging technologies for breast cancer diagnostics
- 5.2.4. End-User: High adoption of breast cancer diagnostics in the diagnostic laboratories
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Breast Cancer Diagnostics Market, by Technique

6.1. Introduction
6.2. Imaging
6.3. Molecular Testing
6.4. Tissue Biopsy Tests

7. Breast Cancer Diagnostics Market, by Cancer Type

7.1. Introduction
7.2. BRCA Breast Cancer
7.3. EGFR Mutation Test Breast Cancer
7.4. ER & PR Breast Cancer
7.5. HER 2 Breast Cancer

8. Breast Cancer Diagnostics Market, by Component

8.1. Introduction
8.2. Consumables
8.3. Instruments

9. Breast Cancer Diagnostics Market, by Diagnostic Type

9.1. Introduction
9.2. Ionizing Breast Imaging Technologies
9.3. Non-Ionizing Imaging Technologies

10. Breast Cancer Diagnostics Market, by End-User

10.1. Introduction
10.2. Diagnostic Laboratories
10.3. Hospitals & Ambulatory Surgery Center
10.4. Research & Academic Institutes

11. Americas Breast Cancer Diagnostics Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Breast Cancer Diagnostics Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Breast Cancer Diagnostics Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. Solis Mammography Announces Acquisition of Carolina Breast Imaging
- 14.3.2. Johnson & Johnson Impact Ventures Invests in Mamotest to Improve Access to Care for Breast Cancer Patients in Latin America
- 14.3.3. Sysmex Europe Distributes MammaTyper, an Advanced Breast Cancer Diagnostic Assay, Through The European Distribution Agreement With Cerca Biotech
14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

15.1. Key Company Profiles
15.2. Key Product Portfolio